IMMUTEP LTD-SP ADR (IMMP) Stock Price, Forecast & Analysis
USA - NASDAQ:IMMP - US45257L1089 - ADR
IMMP Key Statistics, Chart & Performance
The current stock price of IMMP is 1.78 USD. In the past month the price decreased by -6.15%. In the past year, price decreased by -1.35%.
IMMP Latest News, Press Relases and Analysis
IMMP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.92 | 382.62B | ||
| AMGN | AMGEN INC | 13.64 | 160.12B | ||
| GILD | GILEAD SCIENCES INC | 15.06 | 153.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.31 | 108.21B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.98 | 66.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 828.44 | 55.38B | ||
| ARGX | ARGENX SE - ADR | 62.37 | 51.50B | ||
| INSM | INSMED INC | N/A | 38.71B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.11B | ||
| NTRA | NATERA INC | N/A | 26.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.07B | ||
| BIIB | BIOGEN INC | 9.03 | 22.15B |
Related stock screener links
About IMMP
Company Profile
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Company Info
IMMUTEP LTD-SP ADR
Level 32, Suite 32.07 Australia Square, 264 George Street
Sydney NEW SOUTH WALES 2000 AU
CEO: Marc Voigt
Employees: 0
Phone: 61283157003
IMMUTEP LTD-SP ADR / IMMP FAQ
What does IMMUTEP LTD-SP ADR do?
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
What is the current price of IMMP stock?
The current stock price of IMMP is 1.78 USD. The price decreased by -2.73% in the last trading session.
Does IMMUTEP LTD-SP ADR pay dividends?
IMMP does not pay a dividend.
How is the ChartMill rating for IMMUTEP LTD-SP ADR?
IMMP has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is IMMUTEP LTD-SP ADR (IMMP) stock traded?
IMMP stock is listed on the Nasdaq exchange.
How is the market expecting IMMP stock to perform?
9 analysts have analysed IMMP and the average price target is 2.59 USD. This implies a price increase of 45.69% is expected in the next year compared to the current price of 1.78.
Can you provide the sector and industry classification for IMMUTEP LTD-SP ADR?
IMMUTEP LTD-SP ADR (IMMP) operates in the Health Care sector and the Biotechnology industry.
IMMP Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to IMMP. When comparing the yearly performance of all stocks, IMMP turns out to be only a medium performer in the overall market: it outperformed 44.16% of all stocks.
IMMP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMMP. While IMMP seems to be doing ok healthwise, there are quite some concerns on its profitability.
IMMP Financial Highlights
Over the last trailing twelve months IMMP reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS decreased by -14.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.06% | ||
| ROE | -25.43% | ||
| Debt/Equity | 0 |
IMMP Forecast & Estimates
9 analysts have analysed IMMP and the average price target is 2.59 USD. This implies a price increase of 45.69% is expected in the next year compared to the current price of 1.78.
For the next year, analysts expect an EPS growth of -25.63% and a revenue growth 1.99% for IMMP